NCT00860600已完成2 期
The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 4
- 主要终点
- Platelet Response
研究概览
简要总结
This was a phase II multi-center, randomized, open-label study with two parallel study groups to evaluate the efficacy and safety of PG2 in ITP patients.
详细描述
The primary objective of this exploratory study is to evaluate the efficacy of PG2 in raising the platelet counts in ITP patients using two dosing schedules. The secondary objective is to determine the safety of PG2 treatment among these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older.
- •Confirmed diagnosis of chronic ITP, according to The American Society of Hematology (ASH) Guidelines, for at least 6 months and have received one or more prior conventional treatments for ITP.
- •Patient's platelet count of less than 50,000 per cubic millimeter at enrollment, platelet count is calculated from the mean of 2 platelet counts taken during the screening period and that on day
- •The subject or his/her legal delegate has signed an informed consent form.
- •Absence of other conditions that, in the opinion of the investigator, could cause thrombocytopenia.
- •If subjects are currently being treated with corticosteroids, the treatment regimen/dose must have been stable (±25% total dose/day) for a minimum of 4 weeks before screening. However, subjects must remain on a stable treatment regimen. If there is any intent to alter the corticosteroid treatment regimen (e.g., tapering of corticosteroids) before Day 10, subjects may not be included in the study.
- •If subjects are currently being treated with cyclophosphamide, azathioprine or attenuated androgens, the treatment regimen and dose must have been stable (±25% total dose/day) for a minimum of 3 months before screening. However, if there is any intent to alter the treatment regimen before Day 10, subjects may not be included in the study.
- •If a subject is a female of child-bearing potential, she must have a negative result on a urine-based HCG pregnancy test.
- •If a subject is of child-bearing potential, he/she must practice contraception by using a method of proven reliability for the duration of the study.
排除标准
- •The subject has a history of any severe or anaphylactic reaction to blood or any blood-derived product, or any severe reaction to IVIG or any other IgG preparation.
- •The subject is known to be intolerant to any component of the investigational product.
- •The subject has received any live virus vaccine within the last 3 months.
- •The subject has received an IVIG preparation within 1 month prior to screening.
- •The subject is currently receiving, or has received, any investigational agent within one month prior to screening.
- •The subject has received Rituximab within 3 months before screening.
- •The subject is pregnant or is nursing.
- •The subject is diagnosed of having HIV.
- •The subject, at screening, has levels greater than 2.5 times the upper limit of normal liver function of alanine aminotransferase or aspartate aminotransferase.
- •The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for range); or the subject is on dialysis.
- •The subject has a history of deep vein thrombosis (DVT) or thrombotic complications.
- •The subject has any history of hyperviscosity, transient ischemic attack (TIA), stroke, other thromboembolic event, or unstable angina.
- •The subject suffers from any acute or chronic medical conditions (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing enteropathy) that, in the opinion of the investigator, may interfere with the conduct of the study.
- •The subject has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (defined as an absolute neutrophil count (ANC) < 1 x 109/L) or has been diagnosed as non-ITP patients.
- •The subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative.
- •The subject is unwilling or unable to answer the quality of life questionnaires i.e. the BFI.
- •The subject has undergone splenectomy within 4 weeks prior to screening.
研究组 & 干预措施
1. PG2 Treatment: 5 days/week
Experimental
Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
干预措施: PG2 (Drug)
2. PG2 Treatment: 3 days/week
Experimental
Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
干预措施: PG2 (Drug)
结局指标
主要结局
Platelet Response
时间窗: 17 weeks
次要结局
- Patient's fatigue status (measured by the Brief Fatigue Inventory)(17 weeks)
- The endogenous TPO and anti-platelet antibody levels(17 weeks)
- The total number of bleeding events Grade 2 or higher for each subject during the treatment period, or till the time of end-of-study visit for early withdrawal patients(17 weeks)
- The subject incidence of requiring rescue therapy during the treatment period(17 weeks)
- Patient's Bleeding Score (measured by the WHO Bleeding Scale)(17 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
2 期
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical CancerAdultNCT06241781Grit Biotechnology83
进行中（未招募）
2 期
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)Obesity Type 2 Diabetes MellitusNCT06712615ProGen. Co., Ltd.144
已完成
2 期
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorLymphomaNCT03235544Incyte Corporation162
Unknown
2 期
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19Covid19NCT04780685Stemedica Cell Technologies, Inc.40
已完成
2 期
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCNCT04948697BeiGene94